The acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patients

Although trastuzumab therapy is known to be associated with congestive heart failure, its arrhythmogenic potential has not been studied in detail. The purpose of this study was to determine the acute influence of trastuzumab infusion on electrocardiogram (ECG) parameters in patients with metastatic...

Full description

Saved in:
Bibliographic Details
Published in:Swiss medical weekly 2007-10, Vol.137 (39-40), p.556
Main Authors: Yavas, Ozlem, Yazici, Mehmet, Eren, Onder, Oyan, Basak
Format: Article
Language:English
Subjects:
Adult
Aged
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal, Humanized
Antineoplastic Agents - administration & dosage
Breast Neoplasms - drug therapy
Breast Neoplasms - physiopathology
Breast Neoplasms - secondary
Dose-Response Relationship, Drug
Drug Administration Schedule
Electrocardiography - drug effects
Female
Follow-Up Studies
Heart - drug effects
Heart - physiopathology
Humans
Infusions, Intravenous
Middle Aged
Prospective Studies
Trastuzumab
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although trastuzumab therapy is known to be associated with congestive heart failure, its arrhythmogenic potential has not been studied in detail. The purpose of this study was to determine the acute influence of trastuzumab infusion on electrocardiogram (ECG) parameters in patients with metastatic breast cancer. Twenty patients with HER2 overexpressing metastatic breast cancer and normal cardiac function were enrolled in this single-centre prospective study. Standard 12-lead ECG recordings were performed at baseline and after trastuzumab infusion (2 mg/kg given over 30 min). P-wave durations, QT and RR intervals were measured and QT dispersion (QTd) and P-wave dispersion (Pd) were calculated. In comparison with baseline, no statistically significant change in any ECG parameters, including QT and RR intervals, P wave durations, Pd and QTd, was observed after infusion of trastuzumab. In this study, no abnormality of atrial and ventricular depolarisation and repolarisation, indicated by Pd and QTd, was detected after infusion of trastuzumab. As Pd and QTd are both known to be associated with increased risk of serious arrhythmias and sudden death, it would appear that trastuzumab has no acute arrhythmogenic potential related to cardiac depolarisation and repolarisation.
ISSN:1424-7860